Ashwagandha Eases Stress. It Won’t Replace Sleep, Training, or Nutrition.

Educational journalism, not medical advice. Every claim here is checked against its cited sources by editor Tim Bunce — a health writer, not a physician. It isn’t specific to your situation: for health decisions, talk to your own clinician. How we work →

What ashwagandha is, and what extract you’re actually buying

Ashwagandha is the root of an Indian shrub used in Ayurvedic medicine for ~3,000 years. Modern supplements are standardised extracts of the root or root-and-leaf, with the active compounds typically being withanolides. The market has converged on two branded extracts that account for most of the rigorous research: KSM-66 (root only, 5% withanolides minimum) and Sensoril (root and leaf, 10% withanolides). Generic ‘ashwagandha powder’ products vary widely in withanolide content; some have negligible amounts.

This matters for the published evidence: nearly every positive clinical trial used a standardised extract at a known dose. Generic capsules at the same labelled mg may deliver a fraction of the active compound Tandon 2020.

The cortisol-and-stress evidence

Pratte’s 2014 systematic review of 5 RCTs in stressed adults found significant reductions in perceived stress and cortisol after 8-12 weeks of 300-600 mg/day standardised extract Pratte 2014. Lopresti 2019 ran a 60-day RCT in 60 chronically stressed adults and saw 17-23% reductions in morning cortisol and significant improvements in PSS-10 (perceived stress scale) scores compared with placebo Lopresti 2019. Salve 2019’s 8-week RCT showed similar magnitudes Salve 2019. The pattern across this literature:

• Effective doses: 300-600 mg/day of a standardised extract (KSM-66 or Sensoril). Higher doses don’t reliably produce more benefit.
• Time to effect: 4-8 weeks. Reports of ‘next-day’ effects are likely placebo.
• Effect size: cortisol drops typically 15-25%; perceived stress scores drop 30-44% (which sounds large but reflects the high baseline stress in the studied populations).
• Population studied: most trials selected adults with elevated baseline stress. Effects in low-stress populations are smaller and less consistent.

“Ashwagandha root extract demonstrated modest but consistent reductions in serum cortisol and validated stress scores in chronically stressed adults across 5 RCTs. Effect sizes were larger in higher-baseline-stress populations and required 4-12 weeks of daily supplementation.”

— Pratte et al., J Altern Complement Med, 2014 view source

Strength and recovery: where the marketing is ahead of the data

The strength claim originates largely from Wankhede 2015’s 8-week RCT in 57 untrained young men. The ashwagandha group (600 mg/day) gained significantly more strength on bench press and leg extension, and showed greater muscle-circumference increases, than placebo Wankhede 2015. The result was real but limited: the subjects were untrained (where any intervention produces gains), the sample was small (n=57), the trial was funded by a supplement manufacturer, and replication is sparse.

Ziegenfuss 2018’s trial in resistance-trained men found smaller, less reliable effects on strength — closer to the placebo response Ziegenfuss 2018. The 2021 systematic review by Pérez-Gómez and colleagues concluded that ashwagandha’s effects on strength and power are inconsistent and modest at best in trained populations Pérez-Gómez 2020. The supplement is not in the same category as creatine, caffeine, or beta-alanine for strength benefit.

Sleep evidence

The Sanskrit name ashwagandha derives in part from a word that means “sleep-inducing.” Modern trials support this modestly:

• Salve 2020 ran a 6-week RCT in 60 healthy adults and saw improvements in subjective sleep quality (PSQI scores) at 600 mg/day Salve 2020.
• Cheah 2021 meta-analysed 5 RCTs and found small-to-moderate improvements in self-reported sleep quality but limited objective polysomnography evidence Cheah 2021.
• The effect is most reliable in adults with baseline insomnia or significant stress; in already-good sleepers, the additional benefit is small.

Who ashwagandha actually fits

Safety profile: not entirely benign

The published safety profile in healthy adults is generally good at standard doses (300-600 mg/day for ≤12 weeks). But three concerns deserve mention:

• Liver injury: A growing case series in Hepatology Communications and other journals documents drug-induced liver injury (DILI) attributed to ashwagandha in genetically susceptible individuals. Symptoms (jaundice, fatigue, dark urine) typically resolved on discontinuation but required monitoring Bjornsson 2020. Stop and seek medical evaluation if these appear.
• Thyroid effects: ashwagandha can shift thyroid hormones — useful in subclinical hypothyroidism Sharma 2018, problematic in adults already on thyroid medication or with autoimmune thyroid disease.
• Sedation and interaction: at higher doses, mild sedation can occur. Combining with alcohol, benzodiazepines, sleep medications, or central nervous system depressants is unwise.

If you decide to try it

• Choose a standardised extract: KSM-66 or Sensoril. Generic powders without standardised withanolide content are unreliable.
• Dose 300-600 mg/day, divided morning and evening or single morning dose. Higher doses haven’t shown more benefit.
• Take with food: improves absorption and reduces GI complaints.
• Run an 8-12 week trial: most published benefits emerge in this window. Track stress (PSS-10), sleep quality, and one objective marker (resting heart rate, HRV if you have a device).
• Take a break every 12 weeks: limited long-term data; rotation prevents the unknown.
• Stop and consult a physician if: jaundice, dark urine, severe fatigue, persistent rash, mood changes, or thyroid symptoms appear.

What the evidence does NOT support

• “Ashwagandha replaces sleep”: false. The sleep effects are modest improvements in quality, not reduced need for sleep.
• “Ashwagandha is a strength supplement”: insufficient evidence. Effects in trained populations are small and inconsistent.
• “Ashwagandha cures anxiety”: not the same as a treatment for diagnosable anxiety disorder. Modest stress reduction in healthy adults is not a substitute for evidence-based mental health care.
• “Ashwagandha lowers cortisol therefore is anti-aging”: the cortisol-aging chain is far more complex than wellness marketing suggests.
• “Ashwagandha boosts testosterone”: a few small trials show modest testosterone increases in men with reduced baseline levels; effects in eugonadal men are inconsistent and clinically negligible.

Practical takeaways

• Ashwagandha is one of the better-evidenced adaptogens: 5+ RCTs show 15-25% cortisol reduction and meaningful stress-score improvements at 300-600 mg/day for 8-12 weeks.
• Choose a standardised extract (KSM-66 or Sensoril) — generic powders are inconsistent.
• The strength and recovery claims are weaker than marketing suggests; trained athletes should expect modest at best.
• Sleep effects are real but modest; most pronounced in stressed adults with sub-clinical insomnia.
• Safety: thyroid medication interaction, autoimmune contraindication, pregnancy contraindication, recent liver injury reports. Healthy adults at standard doses generally tolerate well.
• Fix sleep, training, and nutrition first. Ashwagandha is a small lever, not a foundation.

How ashwagandha actually works (and how much we really know)

The article so far has described what ashwagandha does — modest, measurable drops in cortisol and stress scores — without explaining how. The honest answer is that the mechanism is better understood in test tubes and rodents than in people. The leading hypothesis centres on the body's main stress-response system, the hypothalamic–pituitary–adrenal (HPA) axis: the chain of glands that releases cortisol when you are under pressure. Steroidal compounds in the root called withanolides — chiefly withaferin A — appear to dampen an over-active HPA axis by suppressing corticotropin-releasing hormone (the brain's "release cortisol" signal) and by making cells more sensitive to the cortisol already circulating, which helps restore the feedback loop that normally switches the stress response off Jamnekar 2025. In other words, the plausible mechanism is normalisation of an over-firing system, not blanket suppression — which fits the clinical pattern of effects showing up mainly in chronically stressed people and barely at all in the calm.

A second strand involves GABA (gamma-aminobutyric acid), the brain's principal "brake" neurotransmitter that quietens nervous-system activity. Withanolides appear to interact with GABA-A receptors to enhance this inhibitory, calming signalling, which would account for the mild sedative and anti-anxiety effects users report Jamnekar 2025. The important caveat is the source of this evidence. Much of it comes from animal experiments, where ashwagandha extracts blunted stress-induced corticosterone surges (the rodent equivalent of cortisol) and normalised brain neurotransmitter levels; the human data showing similar neuroendocrine effects remain limited in scope and duration Jamnekar 2025. So when a label promises a specific "cortisol-blocking" action, treat the molecular story as a reasonable working theory backed by strong preclinical signals and consistent-but-modest human outcomes — not as a fully mapped pharmacological pathway.

The testosterone and fertility question, examined

The "Practical takeaways" section flags a testosterone boost as one of the overstated claims, which is fair as a headline. But the underlying evidence deserves a closer, honest look, because it is more mixed than either the marketing or a flat dismissal suggests. A 2021 systematic review in Advances in Nutrition that examined herbs and male testosterone identified ashwagandha root and root/leaf extracts as one of only two herbal interventions with a genuine positive signal on testosterone concentrations in men Smith 2021. That sounds promising until you read the review's own caveats: across all the herbs it covered, only 6 of 32 studies were judged to be at low risk of bias, and the conclusions are tempered by small sample sizes, widely varying doses and extracts, and a reliance on young, non-clinical populations Smith 2021. A real but fragile signal, in other words — not an established effect.

The fragility shows up clearly in newer, better-controlled work. A 2026 randomised, double-blind, placebo-controlled trial gave 76 healthy men aged 30–50 either 300 mg of a standardised, manufacturer-branded root extract twice daily or placebo for eight weeks. The supplement produced large — and, for a supplement trial, unusually large — statistically significant gains in self-reported sexual desire and erectile-function scores versus placebo, and numerical rises in semen volume, sperm count and motility — yet the change in total testosterone did not reach statistical significance (p = 0.223), and the free-testosterone difference was only borderline (p = 0.099) Khanna 2026. The plain-English reading: ashwagandha may modestly help some aspects of male sexual and reproductive function, possibly through stress reduction and antioxidant effects on sperm rather than a reliable hormonal surge, but it is not a dependable testosterone booster, and any hormonal change is small enough to vanish between studies. The trial authors themselves note that eight weeks is too short to capture long-term endocrine effects and that the modest sample limits how widely the results apply Khanna 2026. If a product is sold primarily as a "test booster," the evidence does not earn that promise.

Medications it can clash with

The earlier safety section covered liver, thyroid and general sedation. What it did not lay out is the specific list of prescription medicines ashwagandha can interact with — the practical detail that matters most if you take anything daily. US health agencies are explicit here. The National Center for Complementary and Integrative Health warns that ashwagandha may interact with medications for diabetes and high blood pressure, with immunosuppressants (drugs that deliberately damp the immune system), with sedatives, with anti-seizure medications, and with thyroid hormone medication NCCIH 2024. The mechanisms are intuitive once spelled out: ashwagandha can lower blood sugar and blood pressure, so stacking it on top of antidiabetic or antihypertensive drugs risks pushing those readings too low; it appears to stimulate immune activity, which can work against immunosuppressants taken after a transplant or for an autoimmune disease; and its calming, GABA-related action can add to the drowsiness of benzodiazepines, sleep aids and anticonvulsants NIH ODS 2023.

The thyroid interaction is worth singling out because it cuts both ways. Ashwagandha can nudge thyroid hormone levels upward, which is why it is generally discouraged for people with thyroid disease — but in someone already taking levothyroxine, that same nudge can tip them toward the symptoms of an overactive thyroid NCCIH 2024. None of this means the supplement is dangerous for the average healthy adult. It means that if you take a regular prescription — especially for diabetes, blood pressure, thyroid, an autoimmune condition, or anything sedating — the right move is to clear ashwagandha with your doctor or pharmacist first, not to start it quietly and hope the doses don't collide NCCIH 2024.

A newer warning: too much, for too long, can backfire

Most of the safety conversation around ashwagandha has focused on rare liver injury. A more recent and counter-intuitive signal deserves a place alongside it: at high doses taken for many months, the very HPA-axis dampening that makes ashwagandha calming can tip into genuine adrenal suppression. A 2026 case report describes a 55-year-old woman who developed Cushingoid features — the puffy face and weight gain seen when cortisol signalling goes badly awry — after taking roughly 950 mg of ashwagandha daily for over a year for knee osteoarthritis. Testing showed abnormally low cortisol and a blunted response to an ACTH stimulation test, the hallmark of a suppressed HPA axis; she needed hydrocortisone replacement, and at three-month follow-up her axis had still not recovered EDM Case Reports 2026. A single case cannot prove how common this is, and her dose sat above the 300–600 mg range used in most trials. But the report's authors make a reasonable point: there are currently no official daily-dose or duration limits for ashwagandha, and both clinicians and the public should know that prolonged, high-dose use can over-suppress the same stress system the supplement is marketed to soothe EDM Case Reports 2026.

This reinforces, with a real-world example, the "take periodic breaks" guidance offered earlier — and it squares with the broader evidence picture. Even the supportive meta-analyses report meaningful drops in cortisol and stress scores while rating the overall certainty of the evidence as limited by small trials and statistical heterogeneity Bachour 2025. The pragmatic conclusion is unchanged but better grounded: ashwagandha is best treated as a short-to-medium-term tool used at standardised, studied doses, not an open-ended daily habit at ever-higher amounts. More is not safer, and US regulators caution that long-term safety data simply do not yet exist NCCIH 2024.

References